DR. HENNESSEY: Thank you. I'm Associate Professor of Medicine at Brown Medical School in Providence, Rhode Island. I've been involved in clinical research with the applications of levothyroxine since 1983, and I have a keen interest in the process to assure that we have reliable and accurate dosing of thyroxine.
I've spoken on this subject at the request of both Forest Pharmaceuticals as well as the Knoll Pharmaceutical, now known as the Abbott Pharmaceutical Company, in the past, but I'm here on my own today, and I've been involved in clinical research protocols sponsored by Knoll, now known as Abbott, and King Pharmaceuticals, in the near future.
At this point in time, L-thyroxine is clinically essential in the treatment of hypothyroidism and thyrotropin suppression in patients with thyroid cancer, as about 95 percent of those with hypothyroidism have primary hypothyroidism, making the serum TSH a useful and convenient parameter to assure appropriate dose titration. TSH indicates the thyroid hormone action at the tissue level and thus is followed with great attention